CompletedNCT04817553
Impact of COVID-19 on the Clinical Outcomes and Management of IgG4 Related Disease Patients
Studying IgG4-related disease
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Chinese University of Hong Kong
- Principal Investigator
- Raymond Tang, MDChinese University of Hong Kong
- Intervention
- exposure to COVID19(other)
- Enrollment
- 124 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2021 – 2023
Study locations (1)
- Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, New Territories, Hong Kong
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04817553 on ClinicalTrials.govOther trials for IgG4-related disease
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT07061938Study to Assess Safety, Efficacy and Persistence of ACE1831, in Subjects With IgG4-Related DiseaseAcepodia Biotech, Inc.
- RECRUITINGPHASE2NCT07025330A Study of Efgartigimod in Patients With IgG4-Related DiseaseStanford University
- RECRUITINGPHASE3NCT07190196A 52-week Study of Rilzabrutinib Efficacy and Safety Compared to Placebo in Adults Diagnosed With IgG4-related DiseaseSanofi
- RECRUITINGPHASE2NCT07148791Exploratory Study of Anti-BCMA-CD19 CAR-T Cell Therapy in Relapsed or Refractory IgG4-Related DiseaseChinese PLA General Hospital
- RECRUITINGPHASE2, PHASE3NCT07068165A Randomized Controlled Study of the Efficacy and Safety of Lenalidomide in the Treatment of Active IgG4-related DiseasePeking Union Medical College Hospital
- RECRUITINGNANCT07104058A Study on the Effect of MRD Detected by FAPI PET / CT on the Recurrence of IgG4-RDLuo Yaping
- ACTIVE NOT RECRUITINGNCT06844864Adaptive and Trained Immunity in the Pathogenesis of IgG4-Related DiseaseIRCCS San Raffaele
- RECRUITINGEARLY PHASE1NCT06497387Safety and Efficacy of PRG-1801 for Refractory Lupus Nephritis and IgG4-Related DiseaseTongji Hospital